Results for tag: "Waldenstrom Macroglobulinemia Drug"

Waldenstrom Macroglobulinemia (WM) is a rare type of non-Hodgkin lymphoma (NHL) that affects the B-cells of the immune system. It is characterized by an overproduction of a type of antibody called IgM. Treatment for WM typically involves chemotherapy, radiation therapy, and/or targeted therapy. Targeted therapy is a type of treatment that uses drugs to target specific molecules involved in the growth and spread of cancer cells. These drugs are designed to block the growth and spread of cancer cells while limiting damage to normal cells. Commonly used targeted therapies for WM include ibrutinib, venetoclax, and obinutuzumab. The WM drug market is a rapidly growing segment of the lymphoma drug market. It is expected to experience strong growth over the forecast period due to the increasing prevalence of WM, the availability of new treatments, and the increasing focus on personalized medicine. Companies in the WM drug market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Gilead Sciences, Janssen Pharmaceuticals, Merck, Novartis, and Pfizer. Show Less Read more